Rational design of a receptor-targeted photodynamic molecular beacon for the multi-level control of singlet oxygen production and PDT activity in cancer cells

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 6449, Issue , 2007, Pages

  Chen, Juan ^a,b   Stefflova, Klara ^b   Warren, Mike ^b   Bu, Jiachuan ^b   Wilson, Brian C ^a   Zheng, Gang ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Control of 1O2 production; Folate receptor; KB cells; MMP7; Molecular beacon; Photodynamic molecular beacon (PMB); Photodynamic therapy; Photosensitizer (PS); Singlet oxygen (1O2); Targeted delivery

Indexed keywords

BIOMARKERS; CELLS; ENZYMES; PHOTODYNAMIC THERAPY; PHOTOSENSITIZERS; TUMORS;

FOLATE RECEPTORS; KB CELLS; MOLECULAR BEACONS; PHOTODYNAMIC MOLECULAR BEACONS (PMB); SINGLET OXYGEN PRODUCTION; TARGETED DELIVERY;

MOLECULAR STRUCTURE;

EID: 34247367176     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.699754     Document Type: Conference Paper

References (24)

1. Dougherty, T.J., et al., Photodynamic therapy. J Natl Cancer Inst, 1998. 90(12): p. 889-905.
2. Moan, J. and K. Berg, The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol, 1991. 53(4): p. 549-53.
3. Oleinick, N.L. and H.H. Evans, The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res, 1998.150(5 Suppl): p. S146-56.
4. Niedre, M.J., et al., In vitro tests of the validity of singlet oxygen luminescence measurements as a dose metric in photodynamic therapy. Cancer Res, 2003. 63(22): p. 7986-94.
5. Pinthus, J.H., et al., Photodynamic therapy for urological malignancies: past to current approaches. J Urol, 2006.175(4): p. 1201-7.
6. Leamon, C.P. and P.S. Low, Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U. S. A., 1991. 88(13): p. 5572-5576.
7. Tyagi, S. and F.R. Kramer, Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol, 1996. 14(3): p. 303-8.
8. Chen, J., et al., Protease-triggered photosensitizing beacon based on singlet oxygen quenching and activation. J Am Chem Soc, 2004.126(37): p. 11450-1.
9. Giambernardi, T.A., et al., Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol, 1998.16(8): p. 483-96.
10. Zheng, G., et al., Low-density lipoprotein reconstituted by pyropheophorbide cholesteryl oleate as target-specific photosensitizer. Bioconjug Chem, 2002.13(3): p. 392-6.
11. Stefflova, K., et al., Photodynamic therapy agent with a built-in apoptosis sensor for evaluating its own therapeutic outcome in situ. J Med Chem, 2006. 49(13): p. 3850-6.
12. Bellnier, D.A., et al., Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Cancer Research, 2003. 63(8): p. 1806-13.
13. Reddy, J.A., V.M. Allagadda, and C.P. Leamon, Targeting therapeutic and imaging agents to folate receptor positive tumors. Current Pharmaceutical Biotechnology, 2005. 6(2): p. 131-50.
14. Lu, Y. and P.S. Low, Folate-mediated delivery of macromolecular anticancer therapeutic agents. Advanced Drug Delivery Reviews, 2002. 54(5): p. 675-93.
15. Sabharanjak, S. and S. Mayor, Folate receptor endocytosis and trafficking. Advanced Drug Delivery Reviews, 2004. 56(8): p. 1099-109.
16. Paulos, C.M., et al., Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Advanced Drug Delivery Reviews, 2004. 56(8): p. 1205-17.
17. Hilgenbrink, A.R. and P.S. Low, Folate receptor-mediated drug targeting: from therapeutics to diagnostics. Journal of Pharmaceutical Sciences, 2005.94(10): p. 2135-46.
18. Ohbayashi, H., Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci, 2002.3(4): p. 409-21.
19. Leinonen, T., et al., Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer, 2006. 51(3): p. 313-21.
20. McCawley, L.J. and L.M. Matrisian, Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today, 2000.6(4): p. 149-56.
21. Shiomi, T. and Y. Okada, MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev, 2003. 22(2-3): p. 145-52.
22. Crawford, H.C., et al., Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest, 2002.109(11): p. 1437-44.
23. Zhang, J., et al., The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis, 2005.26(10): p. 1748-53.
24. Kren, L., et al., Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol, 2006. 42(1): p. 16-9.